Preclinically, we have identified enhanced disease control of an ASS1‐deficient and K12D KRAS‐mutant NSCLC cell line sensitive to ADI‐PEG20 and PD1 blockade.52 The gene discussed is KRAS; the disease is non-small cell lung carcinoma.